Linwei Lu

1.8k total citations
42 papers, 1.4k citations indexed

About

Linwei Lu is a scholar working on Molecular Biology, Biomaterials and Biomedical Engineering. According to data from OpenAlex, Linwei Lu has authored 42 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 16 papers in Biomaterials and 9 papers in Biomedical Engineering. Recurrent topics in Linwei Lu's work include Nanoparticle-Based Drug Delivery (16 papers), RNA Interference and Gene Delivery (12 papers) and Nanoplatforms for cancer theranostics (9 papers). Linwei Lu is often cited by papers focused on Nanoparticle-Based Drug Delivery (16 papers), RNA Interference and Gene Delivery (12 papers) and Nanoplatforms for cancer theranostics (9 papers). Linwei Lu collaborates with scholars based in China, United States and South Korea. Linwei Lu's co-authors include Weiyue Lu, Changyou Zhan, Zhilan Chai, Jingcheng Dong, Zhengxiao Zhao, Cao Xie, Huitong Ruan, Danni Ran, Jianfen Zhou and Kuan Jiang and has published in prestigious journals such as SHILAP Revista de lepidopterología, ACS Nano and Biomaterials.

In The Last Decade

Linwei Lu

41 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Linwei Lu China 20 738 555 528 157 150 42 1.4k
Jianming Liang China 22 881 1.2× 587 1.1× 523 1.0× 51 0.3× 267 1.8× 37 1.7k
Kosuke Shimizu Japan 27 982 1.3× 585 1.1× 386 0.7× 82 0.5× 156 1.0× 89 1.9k
Huae Xu China 27 918 1.2× 558 1.0× 623 1.2× 191 1.2× 155 1.0× 70 2.1k
Guotao Tang China 17 703 1.0× 538 1.0× 349 0.7× 130 0.8× 61 0.4× 63 1.5k
Ruoning Wang China 24 774 1.0× 406 0.7× 449 0.9× 45 0.3× 126 0.8× 48 1.5k
Shaofeng Duan China 27 792 1.1× 338 0.6× 488 0.9× 56 0.4× 148 1.0× 84 1.9k
Hui Ding United States 25 690 0.9× 656 1.2× 479 0.9× 49 0.3× 74 0.5× 55 1.6k
Zhonglian Cao China 26 934 1.3× 373 0.7× 549 1.0× 71 0.5× 271 1.8× 53 2.1k
Chaemin Lim South Korea 18 548 0.7× 360 0.6× 275 0.5× 47 0.3× 95 0.6× 71 1.3k
Jianping Zhou China 29 907 1.2× 801 1.4× 674 1.3× 112 0.7× 117 0.8× 62 2.2k

Countries citing papers authored by Linwei Lu

Since Specialization
Citations

This map shows the geographic impact of Linwei Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linwei Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linwei Lu more than expected).

Fields of papers citing papers by Linwei Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linwei Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linwei Lu. The network helps show where Linwei Lu may publish in the future.

Co-authorship network of co-authors of Linwei Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Linwei Lu. A scholar is included among the top collaborators of Linwei Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linwei Lu. Linwei Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meng, Nana, Jiasheng Lu, Jianfen Zhou, et al.. (2025). Improved immunocompatibility of active targeting liposomes by attenuating nucleophilic attack of cyclic RGD peptides on complement 3. Biomaterials. 321. 123350–123350. 5 indexed citations
2.
Zhou, Jianfen, Nana Meng, Linwei Lu, et al.. (2024). A novel peptide-drug conjugate for glioma-targeted drug delivery. Journal of Controlled Release. 369. 722–733. 12 indexed citations
3.
Ding, Yuan, Zhilan Chai, Jun Wang, et al.. (2024). All-stage targeted red blood cell membrane-coated docetaxel nanocrystals for glioma treatment. Journal of Controlled Release. 369. 325–334. 19 indexed citations
4.
Ding, Yuan, Jianfen Zhou, Nana Meng, et al.. (2024). All-stage targeted nanodiscs for glioma treatment by inducing cuproptosis and apoptosis of cancer cells and cancer stem cells. Asian Journal of Pharmaceutical Sciences. 20(2). 101010–101010. 2 indexed citations
5.
Lu, Linwei, Jianfen Zhou, Nana Meng, et al.. (2023). Influence of lung cancer model characteristics on tumor targeting behavior of nanodrugs. Journal of Controlled Release. 354. 538–553. 16 indexed citations
6.
Luo, Zimiao, Jianfen Zhou, Linwei Lu, et al.. (2022). All-stage targeted therapy for the brain metastasis from triple-negative breast cancer. Acta Pharmaceutica Sinica B. 13(1). 359–371. 16 indexed citations
7.
Luo, Zimiao, Linwei Lu, Nana Meng, et al.. (2022). In vivo self-assembled drug nanocrystals for metastatic breast cancer all-stage targeted therapy. Journal of Controlled Release. 346. 32–42. 24 indexed citations
8.
Wang, Songli, Ruifeng Wang, Nana Meng, et al.. (2022). Engineered platelets-based drug delivery platform for targeted thrombolysis. Acta Pharmaceutica Sinica B. 12(4). 2000–2013. 21 indexed citations
9.
Hu, Yang, Kuan Jiang, Dongli Wang, et al.. (2021). Core-shell lipoplexes inducing active macropinocytosis promote intranasal delivery of c-Myc siRNA for treatment of glioblastoma. Acta Biomaterialia. 138. 478–490. 45 indexed citations
10.
Li, Jinyang, Jiasheng Lu, Jianfen Zhou, et al.. (2020). A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated. Acta Pharmaceutica Sinica B. 11(1). 283–299. 10 indexed citations
11.
Ran, Danni, Jianfen Zhou, Zhilan Chai, et al.. (2020). All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide. Theranostics. 10(9). 4073–4087. 32 indexed citations
12.
Zhao, Zhengxiao, Baojun Liu, Jing Sun, et al.. (2019). Baicalein Inhibits Orthotopic Human Non-Small Cell Lung Cancer Xenografts via Src/Id1 Pathway. Evidence-based Complementary and Alternative Medicine. 2019. 1–7. 26 indexed citations
13.
Lu, Linwei, Mingfei Zhang, Xiaoyi Wang, et al.. (2019). Baicalein enhances the antitumor efficacy of docetaxel on nonsmall cell lung cancer in a β‐catenin‐dependent manner. Phytotherapy Research. 34(1). 104–117. 16 indexed citations
14.
Liu, Lumei, Zhengxiao Zhao, Linwei Lu, et al.. (2019). Icariin and icaritin ameliorated hippocampus neuroinflammation via mediating HMGB1 expression in social defeat model in mice. International Immunopharmacology. 75. 105799–105799. 40 indexed citations
15.
Liu, Lumei, Zhengxiao Zhao, Linwei Lu, et al.. (2019). Icariin and icaritin ameliorated hippocampus neuroinflammation via inhibiting HMGB1-related pro-inflammatory signals in lipopolysaccharide-induced inflammation model in C57BL/6 J mice. International Immunopharmacology. 68. 95–105. 43 indexed citations
16.
Wang, Xiaoyi, Nana Meng, Songli Wang, et al.. (2019). Non-immunogenic, low-toxicity and effective glioma targeting MTI-31 liposomes. Journal of Controlled Release. 316. 381–392. 43 indexed citations
17.
Zhao, Zhengxiao, Baojun Liu, Jing Sun, et al.. (2019). Scutellaria Flavonoids Effectively Inhibit the Malignant Phenotypes of Non-small Cell Lung Cancer in an Id1-dependent Manner. International Journal of Biological Sciences. 15(7). 1500–1513. 38 indexed citations
18.
Chai, Zhilan, Xuefeng Hu, Xiaoli Wei, et al.. (2017). A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery. Journal of Controlled Release. 264. 102–111. 215 indexed citations
19.
Liu, Jiaqi, Ying Wei, Qingli Luo, et al.. (2016). Baicalin attenuates inflammation in mice with OVA-induced asthma by inhibiting NF-κB and suppressing CCR7/CCL19/CCL21. International Journal of Molecular Medicine. 38(5). 1541–1548. 56 indexed citations
20.
Chen, Xishan, Lingyu Tai, Jie Gao, et al.. (2015). A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation. Journal of Controlled Release. 218. 29–35. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jianming Liang Breakdown of academic impact, for papers by Kosuke Shimizu Breakdown of academic impact, for papers by Huae Xu Breakdown of academic impact, for papers by Guotao Tang Breakdown of academic impact, for papers by Ruoning Wang Breakdown of academic impact, for papers by Shaofeng Duan Breakdown of academic impact, for papers by Hui Ding Breakdown of academic impact, for papers by Zhonglian Cao Breakdown of academic impact, for papers by Chaemin Lim Breakdown of academic impact, for papers by Jianping Zhou
Rankless by CCL
2026